losartan has been researched along with Sleep Apnea, Obstructive in 7 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 9.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "Obstructive sleep apnea is characterized by chronic intermittent hypoxia (CIH), which is a risk factor for renal peritubular capillary (PTC) loss, and angiotensin II receptor blockers can alleviate PTC loss." | 7.96 | Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors. ( Chu, Y; Jiang, Z; Wu, J; Yu, Q, 2020) |
| "Ninety-one patients with untreated hypertension underwent a home sleep study (55 were found to have OSA; 36 were not)." | 6.82 | Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. ( Manhem, K; Peker, Y; Rosengren, A; Thunström, E, 2016) |
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 5.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| "Obstructive sleep apnea is characterized by chronic intermittent hypoxia (CIH), which is a risk factor for renal peritubular capillary (PTC) loss, and angiotensin II receptor blockers can alleviate PTC loss." | 3.96 | Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors. ( Chu, Y; Jiang, Z; Wu, J; Yu, Q, 2020) |
| "Ninety-one patients with untreated hypertension underwent a home sleep study (55 were found to have OSA; 36 were not)." | 2.82 | Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. ( Manhem, K; Peker, Y; Rosengren, A; Thunström, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Chu, Y | 1 |
| Jiang, Z | 1 |
| Yu, Q | 1 |
| Jenner, R | 1 |
| Fatureto-Borges, F | 1 |
| Costa-Hong, V | 1 |
| Lopes, HF | 1 |
| Teixeira, SH | 1 |
| Marum, E | 1 |
| Giorgi, DAM | 1 |
| Consolim-Colombo, FM | 1 |
| Bortolotto, LA | 1 |
| Lorenzi-Filho, G | 1 |
| Krieger, EM | 1 |
| Drager, LF | 1 |
| Thunström, E | 2 |
| Manhem, K | 2 |
| Rosengren, A | 2 |
| Peker, Y | 3 |
| White, DP | 1 |
| Yucel-Lindberg, T | 1 |
| Lindberg, C | 1 |
| Zelveian, PA | 1 |
| Oshchepkova, EV | 1 |
| Buniatian, MS | 1 |
| Rogoza, AN | 1 |
| Kraiczi, H | 1 |
| Hedner, J | 1 |
| Grote, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment[NCT00701428] | Phase 4 | 90 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for losartan and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea.
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Case-Control Studies; Continuous Positive Airway P | 2016 |
Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Continuous Positive Airw | 2016 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
4 other studies available for losartan and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors.
Topics: Angiogenesis Inducing Agents; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Body | 2020 |
Association of obstructive sleep apnea with arterial stiffness and nondipping blood pressure in patients with hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2017 |
Is Continuous Positive Airway Pressure an Effective and Practical Antihypertensive Agent?
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Continuous Positive Airway Pressure; Female; Human | 2016 |
[Characteristics of hypotensive effect in patients with arterial hypertension and desaturation signs of obstructive sleep apnea syndrome during sleep].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Pressu | 2004 |